Medicine-induced Cardiac Hemodialysis on COVID-19

PHASE4CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 2, 2023

Primary Completion Date

January 10, 2023

Study Completion Date

January 12, 2023

Conditions
Severe Acute Respiratory Syndrome-related CoronavirusRenal DialysisVaccinesMyocarditis AllergicInfection Viral
Interventions
DRUG

Nifedipine 30 MG

Due to initial availability of drugs and the intensities of the patient's symptoms, Nifedipine was used for initial intervention in preventing acute myocarditis from happening.

DIAGNOSTIC_TEST

Kangzhu BPCB0A-3A

The diagnostic test has been used to confirm objective parameters to guide the intervention drug dosages and accessing the risks in sudden death and long term adverse effects.

BEHAVIORAL

Low Mobility

The behavioral intervention aimed at reducing the risks of sudden and strong blood flows in the patient's system.

DRUG

Enalapril Maleate 10Mg Tab

The intervention aims to reduce the vein flows in Diastolic Blood Pressure, and the risks in blood clot formation and internal vein scratch bleeding.

DRUG

Lansoprazole 30Mg Ec Cap

The intervention aims to server the allergy-inducing proteins to induce renal hemodialysis.

DRUG

Metoprolol Succinate

Metoprolol Succinate is used to control the cardiac artery flow amounts and stabilize the patient's heart rate.

DIETARY_SUPPLEMENT

Coenzyme Q10

200 mg per day is used for supplement with the cardiac interventions.

DIETARY_SUPPLEMENT

d-alpha tocopherol acetate

The 268 mg twice per day dietary healthcare is the patient's usual daily use.

DIETARY_SUPPLEMENT

Omega-3

The 900 mg twice per day dietary healthcare is the patient's usual daily use.

DRUG

Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release

Duloxetine hydrochloride is used for the patient's neurodiverse conditions.

DRUG

Superoxide Dismutase

Superoxide Dismutase is used to substitute the missing of antiviral drugs.

Trial Locations (1)

402762

Residential Address, Chongqing

All Listed Sponsors
lead

Yang I. Pachankis

INDIV